Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification

被引:127
|
作者
Thiele, Juergen [1 ]
Kvasnicka, Hans Michael [1 ]
Muellauer, Leonhard [2 ]
Buxhofer-Ausch, Veronika [3 ]
Gisslinger, Bettina [3 ]
Gisslinger, Heinz [3 ]
机构
[1] Univ Cologne, Inst Pathol, D-50924 Cologne, Germany
[2] Med Univ Vienna, Inst Pathol, Vienna, Austria
[3] Med Univ Vienna, Dept Internal Med 1, Vienna, Austria
关键词
CHRONIC IDIOPATHIC MYELOFIBROSIS; WORLD-HEALTH-ORGANIZATION; BONE-MARROW BIOPSY; CHRONIC MYELOPROLIFERATIVE DISORDERS; POLYCYTHEMIA-VERA; DIAGNOSTIC-CRITERIA; INTEROBSERVER RELIABILITY; DIFFERENTIAL-DIAGNOSIS; PROGNOSTIC-FACTORS; NEOPLASMS;
D O I
10.1182/blood-2010-07-293761
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Controversy persists regarding the role of histopathology in the distinction between essential thrombocythemia (ET) and early-prefibrotic primary myelofibrosis (PMF) presenting with thrombocythemia. To investigate the impact and reproducibility of bone marrow (BM) morphology according to the World Health Organization classification, 295 patients with the presumptive clinical diagnosis of either ET or early PMF were studied. Data of this cohort (Vienna group) were compared with 732 corresponding patients (Cologne group). Evaluating blindly (only age and gender known) BM specimens, the 2 groups of pathologists achieved an overall consensus of 78% regarding the total series and 88% concerning the discrimination between ET versus PMF. In 126 ET and 81 early PMF patients without pretreatment and complete documentation, a 90% concordance with the independently established clinical diagnosis was found. In 12 patients, overlapping of histopathology and some clinical findings between ET and polycythemia vera occurred. Contrasting ET, early PMF showed significant differences of presenting hematologic data and an unfavorable prognosis (estimated mean survival, 14 vs 21 years). Comparison of clinical and survival data of the Vienna cohort with the historical Cologne series revealed an overall congruence. This study highlights the impact of BM morphology for the differentiation between true vs false ET. (Blood. 2011; 117(21): 5710-5718)
引用
收藏
页码:5710 / 5718
页数:9
相关论文
共 50 条
  • [1] Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia
    Barbui, T.
    Thiele, J.
    Vannucchi, A. M.
    Tefferi, A.
    LEUKEMIA, 2013, 27 (10) : 1953 - 1958
  • [2] Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis
    Barbui, Tiziano
    Thiele, Juergen
    Carobbio, Alessandra
    Passamonti, Francesco
    Rumi, Elisa
    Randi, Maria Luigia
    Bertozzi, Irene
    Vannucchi, Alessandro M.
    Gisslinger, Heinz
    Gisslinger, Bettina
    Finazzi, Guido
    Ruggeri, Marco
    Rodeghiero, Francesco
    Rambaldi, Alessandro
    Gangat, Naseema
    Tefferi, Ayalew
    BLOOD, 2012, 120 (03) : 569 - 571
  • [3] Early/prefibrotic primary myelofibrosis in patients who were initially diagnosed with essential thrombocythemia
    Kamiunten, Ayako
    Shide, Kotaro
    Kameda, Takuro
    Ito, Masafumi
    Sekine, Masaaki
    Kubuki, Yoko
    Hidaka, Tomonori
    Akizuki, Keiichi
    Tahira, Yuki
    Toyama, Takanori
    Kawano, Noriaki
    Marutsuka, Kousuke
    Maeda, Kouichi
    Takeuchi, Masanori
    Kawano, Hiroshi
    Sato, Seiichi
    Ishizaki, Junzo
    Shimoda, Haruko
    Yamashita, Kiyoshi
    Matsuoka, Hitoshi
    Shimoda, Kazuya
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2018, 108 (04) : 411 - 415
  • [4] Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis
    Brousseau, Maud
    Parot-Schinkel, Elsa
    Moles, Marie-Pierre
    Boyer, Francoise
    Hunault, Mathilde
    Rousselet, Marie-Christine
    HISTOPATHOLOGY, 2010, 56 (06) : 758 - 767
  • [5] Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis
    Barbui, T.
    Thiele, J.
    Vannucchi, A. M.
    Tefferi, A.
    BLOOD CANCER JOURNAL, 2015, 5 : e337 - e337
  • [6] MicroRNA expression profiling of megakaryocytes in primary myelofibrosis and essential thrombocythemia
    Hussein, Kais
    Theophile, Katharina
    Dralle, Wiebke
    Wiese, Birgitt
    Kreipe, Hans
    Bock, Oliver
    PLATELETS, 2009, 20 (06) : 391 - 400
  • [7] Essential thrombocythemia vs. early/prefibrotic myelofibrosis: Why does it matter
    Barosi, Giovanni
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2014, 27 (02) : 129 - 140
  • [8] The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
    Thiele J.
    Kvasnicka H.M.
    Current Hematologic Malignancy Reports, 2009, 4 (1) : 33 - 40
  • [9] Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease
    Jeryczynski, Georg
    Thiele, Juergen
    Gisslinger, Bettina
    Woelfler, Albert
    Schalling, Martin
    Gleiss, Andreas
    Burgstaller, Sonja
    Buxhofer-Ausch, Veronika
    Sliwa, Thamer
    Schloegl, Ernst
    Geissler, Klaus
    Krauth, Maria-Theresa
    Nader, Alexander
    Vesely, Michael
    Simonitsch-Klupp, Ingrid
    Muellauer, Leonhard
    Beham-Schmid, Christine
    Gisslinger, Heinz
    AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (09) : 885 - 891
  • [10] Idiopathic Myelofibrosis in Children: Primary Myelofibrosis, Essential Thrombocythemia, or Transient Process?
    Slone, Jeremy S.
    Smith, Megan C.
    Seegmiller, Adam C.
    Sidonio, Robert F.
    Yang, Elizabeth
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2013, 35 (07) : 559 - 565